South Korean Biotech Firm Olix Exports MASH Treatment to Eli Lilly for 910 Billion Won

The global pharmaceutical industry is witnessing a significant push in the development of treatments for metabolic associated steatohepatitis (MASH), a liver condition affecting millions worldwide. On Feb. 7, South Korean biotech company Olix Pharmaceuticals made headlines by exporting a MASH treatment candidate to U.S. pharmaceutical giant Eli Lilly for approximately 910 billion won. This move marks a significant milestone in the domestic pharmaceutical and bio industry's efforts to establish a foothold in the competitive MASH treatment market.